Globally elevating the AGE clearance receptor, OST48, does not protect against the development of diabetic kidney disease, despite improving insulin secretion.

Authors

Aowen Zhuang

Published

July 22, 2019

Loading PDF viewer…

Supporters

Support the authors with ResearchCoin

Preprint Server

Topics

DOI

10.1101/710558

License

CC-BY-NC-ND

Other Formats

PDF

Globally elevating the AGE clearance receptor, OST48, does not protect against the development of diabetic kidney disease, despite improving insulin secretion.

Authors

Aowen Zhuang

Published

July 22, 2019

Loading PDF viewer…

Supporters

Support the authors with ResearchCoin

Preprint Server

Topics

DOI

10.1101/710558

License

CC-BY-NC-ND

Other Formats

PDF

Supporters

Support the authors with ResearchCoin

Preprint Server

Topics

DOI

10.1101/710558

License

CC-BY-NC-ND

Other Formats

PDF

Paper

Paper

Paper

Paper

Globally elevating the AGE clearance receptor, OST48, does not protect against the development of diabetic kidney disease, despite improving insulin secretion.

Supporters

Preprint Server

Topics

DOI

License

Other Formats

Globally elevating the AGE clearance receptor, OST48, does not protect against the development of diabetic kidney disease, despite improving insulin secretion.

Supporters

Preprint Server

Topics

DOI

License

Other Formats

Supporters

Preprint Server

Topics

DOI

License

Other Formats